Stockreport

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF - Company discontinued the ONSEMBLE trial in August 2023 to shift focus of clinical development program to first-line RAS-mutated mCRC in agreement with the FDA - - C [Read more]